Alongside medical treatment, adopting healthy habits can help you manage tardive dyskinesia. Find out what experts recommend.

Neurocrine's expanding drug portfolio could drive substantial growth through 2031.

On October 7, 2026, Cerevance announced the top-line results of the Phase 3 ARISE trial for the investigational Parkinson's ...

Tardive Dyskinesia (TD) doesn’t just change the way the body moves. It also changes the way we view that body, in mirrors, in ...

Mentara Therapeutics, a new neuropsychiatry company backed by SPRIM Global Investments, today launched with the acquisition of EM-221, ...

Major Parkinson’s breakthrough as new pill offers hope of treating symptoms and has fewer side-effects - Trial found patients on solengepras had 37 minutes less ‘off’ time each day when dopamine drugs ...

Once-daily tavapadon offers a new Parkinson’s treatment option, with symptom benefits supported by trials and important ...

Dr. Ning Xu of Tsinghua University lost his Nikon microscopy prize when researchers found AI-generated artifacts in his cilia ...

ALPHA | Overview of Technology◾️What is Neurocrine Biosciences' SciTech?Pharmaceutical technology targeting neurotransmission ...

A daily medication for Parkinson’s symptoms has successfully completed a late-stage clinical trial, offering hope for the first significant new treatment in decades.

A new daily pill could help people with Parkinson’s disease live more of their life without symptoms, a trial has found.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of ...